JP2010503386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010503386A5 JP2010503386A5 JP2009527737A JP2009527737A JP2010503386A5 JP 2010503386 A5 JP2010503386 A5 JP 2010503386A5 JP 2009527737 A JP2009527737 A JP 2009527737A JP 2009527737 A JP2009527737 A JP 2009527737A JP 2010503386 A5 JP2010503386 A5 JP 2010503386A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- seq
- chain
- fab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 9
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 6
- 102100035139 Folate receptor alpha Human genes 0.000 claims description 6
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 230000002018 overexpression Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06019399A EP1900752A1 (en) | 2006-09-15 | 2006-09-15 | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| EP06019399.2 | 2006-09-15 | ||
| PCT/EP2007/007944 WO2008031577A1 (en) | 2006-09-15 | 2007-09-12 | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010503386A JP2010503386A (ja) | 2010-02-04 |
| JP2010503386A5 true JP2010503386A5 (enExample) | 2010-10-14 |
| JP5513114B2 JP5513114B2 (ja) | 2014-06-04 |
Family
ID=37737768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527737A Active JP5513114B2 (ja) | 2006-09-15 | 2007-09-12 | 卵巣癌の放射免疫療法のためのヒト抗−葉酸受容体アルファ抗体および抗体フラグメント |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8388972B2 (enExample) |
| EP (2) | EP1900752A1 (enExample) |
| JP (1) | JP5513114B2 (enExample) |
| KR (1) | KR101497045B1 (enExample) |
| AU (1) | AU2007296899B2 (enExample) |
| BR (1) | BRPI0716811B8 (enExample) |
| CA (1) | CA2662005C (enExample) |
| ES (1) | ES2644423T3 (enExample) |
| IL (1) | IL197300A (enExample) |
| MX (1) | MX2009002711A (enExample) |
| NZ (1) | NZ575093A (enExample) |
| RU (1) | RU2464277C2 (enExample) |
| WO (1) | WO2008031577A1 (enExample) |
| ZA (1) | ZA200901328B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| CN105777907B (zh) * | 2010-02-24 | 2020-03-17 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| EP2614084A4 (en) | 2010-09-09 | 2014-02-19 | Purdue Research Foundation | HUMANE FOLAT RECEPTOR BETA ANTIBODIES AND METHOD FOR THEIR USE |
| SG189957A1 (en) * | 2010-11-05 | 2013-06-28 | Morphotek Inc | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| JP5881085B2 (ja) | 2011-03-18 | 2016-03-09 | 国立大学法人 鹿児島大学 | 膵臓癌の治療用及び診断用の組成物 |
| ES2661466T3 (es) * | 2011-04-01 | 2018-04-02 | Immunogen, Inc. | Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1 |
| CN107011439B (zh) * | 2011-07-15 | 2020-11-10 | 卫材R&D管理有限公司 | 抗叶酸受体α抗体及其应用 |
| KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| US9629918B2 (en) | 2012-02-29 | 2017-04-25 | Purdue Research Foundation | Folate receptor alpha binding ligands |
| SG11201500938XA (en) * | 2012-08-31 | 2015-04-29 | Immunogen Inc | Diagnostic assays and kits for detection of folate receptor 1 |
| US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| NZ717140A (en) | 2013-08-30 | 2022-05-27 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
| JP6463744B2 (ja) * | 2013-10-08 | 2019-02-06 | イミュノジェン， インコーポレイテッド | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
| KR101646577B1 (ko) * | 2014-08-14 | 2016-08-09 | 원광대학교산학협력단 | 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물 |
| SG11201704056XA (en) | 2014-11-20 | 2017-06-29 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| RS61010B1 (sr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| ES2808853T3 (es) | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
| CN122075735A (zh) | 2015-09-17 | 2026-05-26 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| KR102584446B1 (ko) | 2016-08-12 | 2023-10-04 | 엘.이.에이.에프. 홀딩스 그룹 엘엘씨. | 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도 |
| WO2018031979A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| EP3706801B1 (en) | 2017-11-08 | 2026-01-14 | L.E.A.F Holdings Group LLC | Platinum complexes and uses thereof |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| WO2019157129A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| CA3090391A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| JP7491573B2 (ja) | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| WO2019157133A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| CA3090384A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) * | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CA3090875A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| US12290518B2 (en) | 2018-02-14 | 2025-05-06 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
| CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| US12048767B2 (en) | 2018-02-14 | 2024-07-30 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| EP3765521A4 (en) | 2018-03-13 | 2022-03-23 | Phanes Therapeutics, Inc. | ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| SG11202111109UA (en) | 2019-04-29 | 2021-11-29 | Immunogen Inc | Biparatopic fr-alpha antibodies and immunoconjugates |
| CA3149914A1 (en) | 2019-08-06 | 2021-02-11 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
| CN111393528B (zh) * | 2020-01-19 | 2023-01-31 | 中国药科大学 | 一种靶向叶酸受体α的单链抗体及其应用 |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| EP4166569A1 (en) * | 2021-10-18 | 2023-04-19 | Fondazione IRCCS Istituto Nazionale dei Tumori | Antibodies directed against alpha-folate receptor |
| CN117700557B (zh) * | 2024-02-05 | 2024-04-30 | 卡秋(江苏)生物科技有限公司 | 一种特异性结合叶酸受体α的抗体或抗原结合片段 |
| CN119757601A (zh) * | 2025-01-06 | 2025-04-04 | 哈尔滨脉图精准技术有限公司 | 一种用于卵巢癌诊断的代谢标志物组合及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| CN1678634A (zh) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| CA2556027C (en) * | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| KR101461408B1 (ko) * | 2005-10-06 | 2014-11-13 | 어드밴스드 엑셀러레이터 어플리케이션즈 에스.에이. | 신규 선택 시스템 |
-
2006
- 2006-09-15 EP EP06019399A patent/EP1900752A1/en not_active Withdrawn
-
2007
- 2007-09-12 JP JP2009527737A patent/JP5513114B2/ja active Active
- 2007-09-12 US US12/441,207 patent/US8388972B2/en active Active
- 2007-09-12 EP EP07802280.3A patent/EP2061813B1/en active Active
- 2007-09-12 KR KR1020097004948A patent/KR101497045B1/ko active Active
- 2007-09-12 MX MX2009002711A patent/MX2009002711A/es not_active Application Discontinuation
- 2007-09-12 BR BRPI0716811A patent/BRPI0716811B8/pt active IP Right Grant
- 2007-09-12 AU AU2007296899A patent/AU2007296899B2/en active Active
- 2007-09-12 ZA ZA200901328A patent/ZA200901328B/xx unknown
- 2007-09-12 ES ES07802280.3T patent/ES2644423T3/es active Active
- 2007-09-12 CA CA2662005A patent/CA2662005C/en active Active
- 2007-09-12 NZ NZ575093A patent/NZ575093A/en unknown
- 2007-09-12 RU RU2009114161/10A patent/RU2464277C2/ru active
- 2007-09-12 WO PCT/EP2007/007944 patent/WO2008031577A1/en not_active Ceased
-
2009
- 2009-02-26 IL IL197300A patent/IL197300A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009114161A (ru) | Антитела и фрагменты антител человека против рецептора фолата альфа для радиоиммунотерапии карциномы яичника | |
| CN101355966B (zh) | 双特异性单链Fv抗体分子及其使用方法 | |
| JP2023025202A5 (enExample) | ||
| JP2019524640A5 (enExample) | ||
| JP2005533001A5 (enExample) | ||
| JP2020510662A5 (enExample) | ||
| JP2024501894A5 (enExample) | ||
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| JP2010535713A5 (enExample) | ||
| JP2009539380A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| TWI641385B (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| JP2019501141A (ja) | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート | |
| JP6876618B2 (ja) | 治療目的のための抗体−ウレアーゼコンジュゲート | |
| WO2013173542A4 (en) | Methods for treating cancer with notch2/3 antibodies | |
| JP2020500834A5 (enExample) | ||
| JP2008515889A5 (enExample) | ||
| JP2020517658A5 (enExample) | ||
| CN108452319A (zh) | 靶向cd20的抗体偶联药物制剂 | |
| CN111848805B (zh) | 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体 | |
| KR20150083840A (ko) | Her3 결합 폴리펩티드 | |
| JP2018512402A5 (enExample) | ||
| JP2023500248A5 (enExample) | ||
| JP2021506817A5 (enExample) | ||
| Ziffels et al. | Antibody-based delivery of cytokine payloads to carbonic anhydrase IX leads to cancer cures in immunocompetent tumor-bearing mice |